Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Adenomyosis 1

Interventions

Cyclophosphamide 9glofitamab 4Whole-Body Irradiation 4Rituximab 4fludarabine phosphate 3fludarabine 3Mycophenolic Acid 3Melphalan 3Doxorubicin 3polatuzumab vedotin 2pirtobrutinib 2pembrolizumab 2obinutuzumab 2Tacrolimus 2Sirolimus 2Prednisone 2Busulfan 2zanubrutinib 1venetoclax 1relmacabtagene autoleucel 1pegfilgrastim 1axicabtagene ciloleucel 1Vincristine 1Triamcinolone 1Specimen Handling 1Receptors, Chimeric Antigen 1Prednisolone 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × Triamcinolone × 1 year × Clear all
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡